Adamas Reports Third Quarter 2014 Financial Results

Go back to Adamas Reports Third Quarter 2014 Financial Results

Adamas Pharmaceuticals (ADMS) Misses Q3 EPS by 13c

November 4, 2014 4:58 PM EST

Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q3 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.

... More